Market Overview:
The global acute ischemic stroke drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of stroke, rising geriatric population, and technological advancements in the field of stroke treatment. Based on type, the global acute ischemic stroke drugs market can be segmented into tablets, capsules, and other types. The tablets segment is expected to account for a major share of the global market due to their high demand and widespread use across hospitals and diagnostic centers. Based on application, the global acute ischemic stroke drugs market can be divided into hospitals, diagnostic centers, and others segments.
Product Definition:
A drug used to treat an acute ischemic stroke, which is a type of stroke caused by a blocked blood vessel. These drugs help dissolve the clot and improve blood flow to the brain.
Tablet:
Stroke is one of the leading causes of death in the U.S. According to the CDC, each year stroke costs more than USD 100 billion in direct medical costs and lost productivity due to disability. The economic burden on society is so high that it has been considered as a national emergency by some organizations such as America's Health Insurance Plans (AHIP) and National Association of State Stroke Prevention Partners (NASPP).
Capsule:
Capsule is a gelatin-based shell that contains drug substance and a coating of inert filler material. It is used to protect the drug from degradation, oxidation, and interaction with other drugs in the gastrointestinal tract. Capsules are available in different sizes (length & width) and shapes (cushion-shaped, capsule-shaped). The choice of capsule depends on various factors such as type of active ingredient, dosage formulation requirements etc.
Application Insights:
Based on application, the global acute ischemic stroke drugs market is segmented into hospitals, diagnostic centers and others. The hospitals segment dominated the market in 2017 due to factors such as increasing prevalence of chronic diseases and rising geriatric population. This segment is also anticipated to be fastest-growing over the forecast period owing to factors such as increasing number of hospital construction projects and initiatives by governments across countries for improving healthcare infrastructure.
The diagnostic centers segment was estimated to be worth USD 544 million in 2017 owing to presence of key players engaged in R&D activities for developing effective treatment options for AIS. Furthermore, an increase in incidence rate coupled with aging population prone toward cardiovascular diseases will boost demand for acute ischemic stroke drugs at a significant rate over the forecast period globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high healthcare expenditure are some of the factors responsible for its large share. For instance, as per a research published by Stroke Council in 2016; acute ischemic stroke accounts for approximately 15% to 25% of all admissions to hospitals and 7% to 14% of all hospital days within the United States.
Asia Pacific region is expected to grow at fastest rate during the forecast period owing rising awareness levels regarding early diagnosis & treatment options leading towards improved patient care experience & outcomes thereby driving growth across this region.
Growth Factors:
- Increasing incidence of stroke: The incidence of stroke is increasing globally due to the aging population and rising rates of obesity, hypertension, and diabetes. This is expected to drive the demand for acute ischemic stroke drugs in the coming years.
- Growing awareness about strokes and their prevention: There is a growing awareness among people about strokes and their prevention measures. This is likely to boost the demand for acute ischemic stroke drugs in the near future.
- Technological advancements in drug development: The technological advancements in drug development are helping researchers develop better drugs for treating various diseases, including strokes. This is likely to propel the growth of the global market for acute ischemic stroke drugs in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Acute Ischemic Stroke Drugs Market Research Report
By Type
Tablet, Capsule, Other
By Application
Hospitals, Diagnostic Centers, Others
By Companies
Sanofi, Biogen, Bayer, Pfizer, Roche, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb, Johnson＆Johnson, AstraZeneca, ZZ Biotech, NoNO Inc, Athersys, SanBio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
162
Number of Tables & Figures
114
Customization Available
Yes, the report can be customized as per your need.
Global Acute Ischemic Stroke Drugs Market Report Segments:
The global Acute Ischemic Stroke Drugs market is segmented on the basis of:
Types
Tablet, Capsule, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Biogen
- Bayer
- Pfizer
- Roche
- Boehringer Ingelheim
- Daiichi Sankyo
- Bristol-Myers Squibb
- Johnson＆Johnson
- AstraZeneca
- ZZ Biotech
- NoNO Inc
- Athersys
- SanBio
Highlights of The Acute Ischemic Stroke Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablet
- Capsule
- Other
- By Application:
- Hospitals
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acute Ischemic Stroke Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acute ischemic stroke drugs are medications that can help to improve the symptoms of a stroke. These medications can include aspirin, ibuprofen, and other painkillers. They may also include clot-busting drugs such as tPA (tissue plasminogen activator).
Some of the major players in the acute ischemic stroke drugs market are Sanofi, Biogen, Bayer, Pfizer, Roche, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb, Johnson＆Johnson, AstraZeneca, ZZ Biotech, NoNO Inc, Athersys, SanBio.
The acute ischemic stroke drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acute Ischemic Stroke Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acute Ischemic Stroke Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acute Ischemic Stroke Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acute Ischemic Stroke Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acute Ischemic Stroke Drugs Market Size & Forecast, 2018-2028
4.5.1 Acute Ischemic Stroke Drugs Market Size and Y-o-Y Growth
4.5.2 Acute Ischemic Stroke Drugs Market Absolute $ Opportunity
Chapter 5 Global Acute Ischemic Stroke Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Acute Ischemic Stroke Drugs Market Size Forecast by Type
5.2.1 Tablet
5.2.2 Capsule
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Acute Ischemic Stroke Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Acute Ischemic Stroke Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Diagnostic Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acute Ischemic Stroke Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acute Ischemic Stroke Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Acute Ischemic Stroke Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Acute Ischemic Stroke Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Acute Ischemic Stroke Drugs Market Size Forecast by Type
9.6.1 Tablet
9.6.2 Capsule
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Acute Ischemic Stroke Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Diagnostic Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Acute Ischemic Stroke Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Acute Ischemic Stroke Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Acute Ischemic Stroke Drugs Market Size Forecast by Type
10.6.1 Tablet
10.6.2 Capsule
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Acute Ischemic Stroke Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Diagnostic Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Acute Ischemic Stroke Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Acute Ischemic Stroke Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Acute Ischemic Stroke Drugs Market Size Forecast by Type
11.6.1 Tablet
11.6.2 Capsule
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Acute Ischemic Stroke Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Diagnostic Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Acute Ischemic Stroke Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Acute Ischemic Stroke Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Acute Ischemic Stroke Drugs Market Size Forecast by Type
12.6.1 Tablet
12.6.2 Capsule
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Acute Ischemic Stroke Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Diagnostic Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Acute Ischemic Stroke Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Acute Ischemic Stroke Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Acute Ischemic Stroke Drugs Market Size Forecast by Type
13.6.1 Tablet
13.6.2 Capsule
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Acute Ischemic Stroke Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Diagnostic Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acute Ischemic Stroke Drugs Market: Competitive Dashboard
14.2 Global Acute Ischemic Stroke Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Biogen
14.3.3 Bayer
14.3.4 Pfizer
14.3.5 Roche
14.3.6 Boehringer Ingelheim
14.3.7 Daiichi Sankyo
14.3.8 Bristol-Myers Squibb
14.3.9 Johnson＆Johnson
14.3.10 AstraZeneca
14.3.11 ZZ Biotech
14.3.12 NoNO Inc
14.3.13 Athersys
14.3.14 SanBio
